Rhumbline Advisers Arcturus Therapeutics Holdings Inc. Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 40,137 shares of ARCT stock, worth $878,197. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,137

Previous 33,501 19.81%

Holding current value

$878,197

Previous $354,000 47.46%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$8.91 - $14.41 $59,126 - $95,624	6,636 Added 19.81%	40,137 $522,000
Q1 2025 Apr 08, 2025	BUY	$10.59 - $20.83 $4,839 - $9,519	457 Added 1.38%	33,501 $387,000
Q4 2024 May 29, 2025	SELL	$14.82 - $25.48 $6,772 - $11,644	-457 Reduced 1.36%	33,044 $560,000
Q4 2024 Jan 30, 2025	BUY	$14.82 - $25.48 $696 - $1,197	47 Added 0.14%	33,044 $560,000
Q3 2024 Nov 12, 2024	SELL	$18.08 - $25.38 $21,497 - $30,176	-1,189 Reduced 3.48%	32,997 $765,000
Q2 2024 Aug 01, 2024	SELL	$24.35 - $44.39 $82,351 - $150,126	-3,382 Reduced 9.0%	34,186 $832,000
Q1 2024 May 09, 2024	BUY	$31.23 - $42.99 $44,003 - $60,572	1,409 Added 3.9%	37,568 $1.27 Million
Q4 2023 Feb 08, 2024	SELL	$17.71 - $32.97 $4,923 - $9,165	-278 Reduced 0.76%	36,159 $1.14 Million
Q3 2023 Nov 09, 2023	BUY	$25.44 - $37.35 $17,172 - $25,211	675 Added 1.89%	36,437 $930,000
Q2 2023 Aug 08, 2023	BUY	$23.94 - $32.36 $128,390 - $173,546	5,363 Added 17.64%	35,762 $1.03 Million
Q1 2023 May 11, 2023	BUY	$14.72 - $23.97 $17,943 - $29,219	1,219 Added 4.18%	30,399 $729,000
Q4 2022 Feb 14, 2023	BUY	$14.14 - $23.06 $12,938 - $21,099	915 Added 3.24%	29,180 $495,000
Q3 2022 Nov 10, 2022	BUY	$13.05 - $22.13 $33,499 - $56,807	2,567 Added 9.99%	28,265 $419,000
Q2 2022 Aug 11, 2022	SELL	$12.26 - $31.17 $15,067 - $38,307	-1,229 Reduced 4.56%	25,698 $404,000
Q1 2022 May 12, 2022	SELL	$17.64 - $39.57 $42,547 - $95,442	-2,412 Reduced 8.22%	26,927 $726,000
Q4 2021 Feb 10, 2022	SELL	$34.2 - $47.56 $10,362 - $14,410	-303 Reduced 1.02%	29,339 $1.09 Million
Q3 2021 Nov 12, 2021	BUY	$27.88 - $58.25 $27,183 - $56,793	975 Added 3.4%	29,642 $1.42 Million
Q2 2021 Aug 05, 2021	BUY	$25.79 - $42.11 $187,931 - $306,855	7,287 Added 34.08%	28,667 $970,000
Q1 2021 May 06, 2021	SELL	$38.75 - $86.92 $133,803 - $300,134	-3,453 Reduced 13.9%	21,380 $883,000
Q4 2020 Feb 10, 2021	BUY	$34.61 - $123.66 $275,807 - $985,446	7,969 Added 47.25%	24,833 $1.08 Million
Q3 2020 Nov 12, 2020	SELL	$37.49 - $63.19 $17,207 - $29,004	-459 Reduced 2.65%	16,864 $723,000
Q2 2020 Aug 13, 2020	BUY	$12.66 - $58.27 $219,309 - $1.01 Million	17,323 New	17,323 $810,000

Others Institutions Holding ARCT

# of Institutions

171

Shares Held

25.9M

Call Options Held

321K

Put Options Held

136K

View Full List

About Arcturus Therapeutics Holdings Inc.

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $581M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

More about ARCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Arcturus Therapeutics Holdings Inc. Transaction History